Volume 7, issue 3, June 2020

14 articles in this issue

Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology

Authors
- Frank M. Longo
- Stephen M. Massa
- Content type: Editorial
- Open Access
- Published: 13 May 2020
- Pages: 138 - 139
A Is for Amyloid

Authors
- D. J. Selkoe
- Content type: Editorial
- Published: 28 April 2020
- Pages: 140 - 141
An Industry Perspective: Future of Anti-Amyloid Trials

Authors
- Lynn D. Kramer
- Content type: Editorial
- Published: 28 April 2020
- Pages: 142 - 143
Screening for Mild Cognitive Impairment: There is the Will but Is There a Way?

Authors
- James E. Galvin
- Content type: Editorial
- Open Access
- Published: 06 April 2020
- Pages: 144 - 145
The Future of Anti-Amyloid Trials

Authors (first, second and last of 10)
- P. S. Aisen
- J. Cummings
- EU/US CTAD 2019 Task Force
- Content type: CTAD Task Force Paper
- Open Access
- Published: 17 April 2020
- Pages: 146 - 151
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

Authors (first, second and last of 14)
- Serge Gauthier
- P. S. Aisen
- EU/US CTAD Task Force
- Content type: CTAD Task Force Paper
- Open Access
- Published: 06 April 2020
- Pages: 152 - 157
Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies

Authors (first, second and last of 15)
- Marwan N. Sabbagh
- M. Boada
- H. Hampel
- Content type: Reviews
- Open Access
- Published: 06 March 2020
- Pages: 158 - 164
Early Detection of Mild Cognitive Impairment (MCI) in Primary Care

Authors (first, second and last of 14)
- Marwan N. Sabbagh
- M. Boada
- H. Hampel
- Content type: Reviews
- Open Access
- Published: 06 April 2020
- Pages: 165 - 170
Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting

Authors (first, second and last of 14)
- Marwan N. Sabbagh
- M. Boada
- H. Hampel
- Content type: Reviews
- Open Access
- Published: 06 April 2020
- Pages: 171 - 178
Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer’s Disease Spectrum

Authors (first, second and last of 5)
- T. E. Goldberg
- P. D. Harvey
- Jesus J. Gomar
- Content type: Original Research
- Published: 09 January 2020
- Pages: 179 - 183
Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline

Authors (first, second and last of 12)
- Linda M. P. Wesselman
- A. K. Schild
- S. A. M. Sikkes
- Content type: Original Research
- Open Access
- Published: 02 March 2020
- Pages: 184 - 194
Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business

Authors
- P. S. Aisen
- R. Raman
- Content type: Viewpoint
- Published: 06 March 2020
- Pages: 195 - 196
Impact of the Covid-19 Outbreak on the Clinical and Research Activities of Memory Clinics: An Alzheimer’s Disease Center Facing the Covid-19 Crisis

Authors
- Pierre Jean Ousset
- B. Vellas
- Content type: Viewpoint
- Published: 06 April 2020
- Pages: 197 - 198
The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux

Authors
- Lon S. Schneider
- Content type: Commentary
- Published: 13 May 2020
- Pages: 199 - 200

Volume 7, issue 3, June 2020

Next-generation Alzheimer’s Therapeutics: Leveraging Deep Biology

A Is for Amyloid

An Industry Perspective: Future of Anti-Amyloid Trials

Screening for Mild Cognitive Impairment: There is the Will but Is There a Way?

The Future of Anti-Amyloid Trials

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report

Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) supported by Emerging Digital Technologies

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care

Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting

Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer’s Disease Spectrum

Targeting Lifestyle Behavior to Improve Brain Health: User-Experiences of an Online Program for Individuals with Subjective Cognitive Decline

Futility Analyses in Alzheimer’s Disease (AD) Clinical Trials: A Risky Business

Impact of the Covid-19 Outbreak on the Clinical and Research Activities of Memory Clinics: An Alzheimer’s Disease Center Facing the Covid-19 Crisis

The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux

For authors

Working on a manuscript?

Explore

Volume 7, issue 3, June 2020

Authors

Authors

Authors

Authors

Authors (first, second and last of 10)

Authors (first, second and last of 14)

Authors (first, second and last of 15)

Authors (first, second and last of 14)

Authors (first, second and last of 14)

Authors (first, second and last of 5)

Authors (first, second and last of 12)

Authors

Authors

Authors

For authors

Working on a manuscript?

Explore